VEEV - TimesSquare Capital U.S. FOCUS Growth Equity Q2 2024 Commentary
2024-07-16 05:30:00 ET
Summary
- TimesSquare Capital U.S. Small Cap Growth portfolio outperformed the Russell 2000® Growth Index in the second quarter.
- The portfolio outperformed the Russell Midcap Growth Index in the second quarter.
- Pulling back by -27% was Legend Biotech, a biotechnology developer of cell therapies to treat blood cancers such as multiple myeloma and leukemia.
- At the midway point of 2024, as expected, fields of vision were occupied by central banks and election booths.
| Performance |
| Annualized |
| 2Q24 |
| 1YR |
| 3YR |
| 5YR |
| 7YR |
| 10YR |
| FOCUS Growth Equity Composite (Gross) |
| 0.08% |
| 25.82% |
| 10.13% |
| 16.41% |
| 16.65% |
| 13.04% |
| FOCUS Growth Equity Composite (Net) |
| -0.13% |
| 24.68% |
| 9.07% |
| 15.29% |
| 15.52% |
| 11.93% |
| Russell Midcap® Growth Index |
| -3.21% |
| 15.05% |
| -0.08% |
| 9.92% |
| 11.68% |
| 10.51% |